Myriam Chalabi: Looking forward to reading all the exciting lower GI abstracts!
Myriam Chalabi shared a post by ESMO on X, adding:
“May 7th. ESMO24 deadline!
Looking forward to reading all the exciting CRC/lower GI abstracts! And submitting some…!
Jenny Seligmann as CRC track chair.”
Quoting ESMO’s post:
“ESMO24: Because your research matters – help us shape the future of cancer care.
Submit your abstract by 7 May 2024.”
Source: Myriam Chalabi/X and ESMO/X
Myriam Chalabi, a medical oncologist and researcher based at the Netherlands Cancer Institute, specializes in gastrointestinal tract cancer. Her research primarily focuses on immunotherapy for gastrointestinal cancers.
In 2017, she initiated a clinical investigation called the NICHE trial, aiming to explore the potential benefits of immunotherapy for early-stage colon cancer patients. Through this trial, Dr. Chalabi identified a subtype of colon cancer patients deficient in mismatch repair, exhibiting DNA replication errors, who demonstrate remarkable responsiveness to immunotherapy.
She possesses expertise in neoadjuvant immunotherapies for these specific indications. Additionally, Dr. Chalabi underscores the significance of biomarkers in patient selection for immuno-oncology clinical trials.